Research Article
HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Table 4
Univariate predictors of treatment response for HER2+ breast cancer patients receiving neoadjuvant chemotherapy.
| Variable | OR (95% CL OR) | value |
| Age | 1.01 (0.99-1.04) | 0.3758 | HER2 absolute copy number | 1.07 (1.03-1.1) | <0.0001 | HER2/CEP17 ratio | 1.07 (1.02-1.14) | 0.0142 | IHC_STAIN_PER | | <0.0001a | 3+ 100% vs. 2+ | 6.49 (2.60-16.25) | <0.0001 | 3+ <100% vs. 2+ | 1.88 (0.63-5.61) | 0.2612 | Clinical stage | | 0.0246a | 1 vs. 3 | 4.78 (1.64-15.41) | 0.0067 | 2 vs. 3 | 1.58 (0.81-3.12) | 0.1797 | Tumor grade biopsy | | 0.4041a | I vs. III | 0.16 (0.0-5.44) | 0.3294 | II vs. III | 0.73 (0.4-1.36) | 0.3231 | Pretreatment tumor size | 0.85 (0.74-0.97) | 0.0142 | ER expression | | | Negative (<10%) | 2.03 (1.08-3.90) | 0.0304 | Positive (10-100%) | Ref. | | Hormone sensitive (ER or PgR+) | | | Negative (<10%) | 2.44 (1.32-4.53) | 0.0046 | Positive (10-100%) | Ref. | |
|
|
Probabilities modeled are cumulated over the lower ordered RCB values. a value is associated with Type 3 analysis of effects. |